Neurological efficacy and safety of RNA therapeutics in hereditary transthyretin amyloidosis: a systematic review and meta-analysis of randomized controlled trials
Therapeutic Advances in Cardiovascular Disease · 2025-11 · 19
DOI: 10.1177/17539447251390782 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Therapeutic Advances in Cardiovascular Disease, online erschienen am 12.11.2025. Verfasst von Maha Sajjad und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, King Edward Medical University, Lahore, Pakistan. Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial, Oligonucleotides, Antisense, Prealbumin, RNA, Small Interfering. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Hereditary transthyretin amyloidosis (hATTR) is caused by mutations in the transthyretin (TTR) gene, which lead to the aggregation of misfolded TTR protein and amyloid accumulation in the peripheral nerves, heart, and gastrointestinal tract. Recently, RNA therapeutics, including small interfering RNAs (siRNAs) and antisense oligonucleotides (ASOs), have been approved for treating patients with hATTR.
Objectives
To assess the neurological efficacy and safety of RNA therapeutics in hATTR patients.
Design
Systematic review and meta-analysis. Data sources and methods: A systematic literature search was conducted on PubMed, Cochrane, and ClinicalTrials.gov from inception to August 14, 2024. Outcomes included changes from baseline in the Norfolk Quality of Life–Diabetic Neuropathy (Norfolk QOL-DN) score and the modified Neuropathy Impairment Score +7 (mNIS + 7), modified body mass index (mBMI), adverse effects, serious adverse events, and all-cause mortality.
Results
Our study included four RCTs with 842 patients (568 in the RNA therapeutics group and 274 in the placebo group). RNA therapeutics significantly improved Norfolk QoL-DN (mean difference (MD), −18.79; 95% CI, −22.32 to −15.25; p < 0.00001; I 2 = 28%) and mNIS + 7 scores (MD, −26.90; 95% CI, −31.67 to −22.13; p < 0.00001; I 2 = 61%), with significant preservation of mBMI (MD, 114.98; 95% CI, 90.64–139.32; p < 0.00001; I 2 = 59%) compared to placebo. There were no significant differences between the two groups regarding the risk of adverse effects (risk ratio (RR), 0.89; 95% CI, 0.69–1.15; p = 0.36; I 2 = 34%), serious adverse effects (RR, 0.70; 95% CI, 0.31–1.58; p = 0.39; I 2 = 20%), and all-cause mortality (RR, 0.70; 95% CI, 0.31 to 1.58; p = 0.39; I 2 = 20%).
Conclusion
RNA therapeutics are effective and well-tolerated in patients with hATTR, significantly improving quality of life and the progression of neurological impairment. siRNAs demonstrate better outcomes compared to ASOs.
Trial registration
PROSPERO (CRD42024568346).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, King Edward Medical University, Lahore, Pakistan.
- Department of Medicine, Karachi Medical and Dental College, Karachi, Pakistan.
- Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan.
- Department of Medicine, Jinnah Sindh Medical University, Karachi, Pakistan.
- Department of Medicine, Liaquat University of Medical and Health Sciences, Jamshoro, Pakistan.
- Department of Medicine, Jinnah Sindh Medical University, 3/16 B Survey #79 Golden town, Wireless gate, Malir, Karachi 75050, Pakistan.
ORCID-Profile: Maha Sajjad, Rabia Ashraf, Riya Bhagwan, Hassan Ijaz, Ayesha Ejaz, Amna Hussain, Umaimah Naeem
Zitieren
APA
Sajjad, M., Ashraf, R., Bhagwan, R., Ijaz, H., Ejaz, A., Qadeer Ud Din, H., Hussain, A., Khan, M. M., Naeem, U., & Ali, A. (2025). Neurological efficacy and safety of RNA therapeutics in hereditary transthyretin amyloidosis: a systematic review and meta-analysis of randomized controlled trials. Therapeutic Advances in Cardiovascular Disease, 19. https://doi.org/10.1177/17539447251390782
Vancouver
Sajjad M, Ashraf R, Bhagwan R, Ijaz H, Ejaz A, Qadeer Ud Din H, et al. Neurological efficacy and safety of RNA therapeutics in hereditary transthyretin amyloidosis: a systematic review and meta-analysis of randomized controlled trials. Therapeutic Advances in Cardiovascular Disease. 2025;19. doi:10.1177/17539447251390782
BibTeX
@article{Sajjad2025,
author = {Sajjad, Maha and Ashraf, Rabia and Bhagwan, Riya and Ijaz, Hassan and Ejaz, Ayesha and Qadeer Ud Din, Hifza and Hussain, Amna and Khan, Muhammad Mohsin and Naeem, Umaimah and Ali, Aizaz},
title = {Neurological efficacy and safety of RNA therapeutics in hereditary transthyretin amyloidosis: a systematic review and meta-analysis of randomized controlled trials},
journal = {Therapeutic Advances in Cardiovascular Disease},
year = {2025},
volume = {19},
doi = {10.1177/17539447251390782}
}
EUVIMED